13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001475373
Total reported value
$461.0M
$461.0M
28 檔
30.9%
During the Q1 2024 filing period, Sector Gamma As (CIK: 0001475373) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $461.0M across 28 reported positions.
In Q1 2024, Sector Gamma As adopted a defensive or profit-taking posture, trimming 15 positions and completely liquidating 6 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | MDT | Medtronic plc | Stock-Healthcare | 10.12% | +0.24% | -5.33% | |
| 2 | PFE | Pfizer Inc | Stock-Healthcare | 9.69% | -1.99% | +13.33% | |
| 3 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 7.62% | -2.78% | +33.05% | |
| 4 | CVS | Cvs Health CORP | Stock-Healthcare | 6.92% | +1.19% | +40.64% | |
| 5 | CAH | Cardinal Health Inc | Stock-Healthcare | 5.76% | -0.64% | +11.13% | |
| 6 | GILD | Gilead Sciences Inc | Stock-Healthcare | 5.48% | -1.75% | EXIT | |
| 7 | ELV | Elevance Health Inc | Stock-Healthcare | 5.01% | +0.69% | +23.34% | |
| 8 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 4.50% | -0.67% | -14.29% | |
| 9 | INCY | Incyte CORP | Stock-Healthcare | 4.25% | -0.26% | -33.56% | |
| 10 | BAX | Baxter International Inc | Stock-Healthcare | 3.89% | — | -1.53% | |
| 11 | BIIB | Biogen Inc | Stock-Healthcare | 3.63% | -1.36% | -41.61% | |
| 12 | UHS | Universal Health Services-b | Stock-Healthcare | 3.59% | — | — | |
| 13 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 3.28% | +0.56% | +42.58% | |
| 14 | GEHC | GE Healthcare Technology | Stock-Healthcare | 3.16% | +0.77% | -50.26% | |
| 15 | BRKR | Bruker CORP | Stock-Healthcare | 2.99% | -0.18% | -11.42% | |
| 16 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 2.88% | +0.05% | -43.02% | |
| 17 | THC | Tenet Healthcare CORP | Stock-Healthcare | 2.30% | — | -59.88% | |
| 18 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.14% | +0.26% | +21.03% | |
| 19 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.00% | +0.46% | -5.60% | |
| 20 | ALKS | Alkermes plc | Stock-Healthcare | 1.93% | — | +26.16% | |
| 21 | GMED | Globus Medical Inc - A | Stock-Healthcare | 1.59% | — | -55.04% | |
| 22 | VTRS | Viatris Inc | Stock-Healthcare | 1.41% | — | — | |
| 23 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.35% | — | — | |
| 24 | QGEN | Qiagen N.V. | Stock-Healthcare | 1.25% | — | — | |
| 25 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.16% | — | -14.05% | |
| 26 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 0.93% | -1.67% | EXIT | |
| 27 | ILMN | Illumina Inc | Stock-Healthcare | 0.66% | — | -58.12% | |
| 28 | CNC | Centene CORP | Stock-Healthcare | 0.49% | +1.00% | -89.73% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | UHS | Universal Health Services-b | +3.6% | NEW | New buy |
| 2 | BMY | Bristol-myers Squibb Co | +3% | +33.05% | Add |
| 3 | CVS | Cvs Health CORP | +2.7% | +40.64% | Add |
| 4 | PFE | Pfizer Inc | +2.1% | +13.33% | Add |
| 5 | ELV | Elevance Health Inc | +1.8% | +23.34% | Add |
| 6 | CAH | Cardinal Health Inc | +1.7% | +11.13% | Add |
| 7 | BIO | Bio-rad Laboratories-a | +1.4% | +42.58% | Add |
| 8 | MDT | Medtronic plc | +1.4% | -5.33% | Trim |
| 9 | VTRS | Viatris Inc | +1.4% | NEW | New buy |
| 10 | AGIO | Agios Pharmaceuticals Inc | +1.4% | NEW | New buy |
| 11 | QGEN | Qiagen N.V. | +1.3% | NEW | New buy |
| 12 | BAX | Baxter International Inc | +0.8% | -1.53% | Trim |
| 13 | BRKR | Bruker CORP | +0.7% | -11.42% | Trim |
| 14 | ALKS | Alkermes plc | +0.6% | +26.16% | Add |
| 15 | IONS | Ionis Pharmaceuticals Inc | +0.4% | +21.03% | Add |
| 16 | ZBH | Zimmer Biomet Holdings Inc | +0.3% | -14.29% | Trim |
| 17 | LNTH | Lantheus Holdings Inc | +0.1% | +1.42% | Add |
| 18 | BMRN | Biomarin Pharmaceutical Inc | 0% | -5.60% | Trim |
| 19 | ALNY | Alnylam Pharmaceuticals Inc | -0.3% | -14.05% | Trim |
| 20 | VIR | Vir Biotechnology Inc | -0.4% | EXIT | Sold out |
| 21 | EW | Edwards Lifesciences CORP | -0.6% | -43.02% | Trim |
| 22 | ILMN | Illumina Inc | -0.7% | -58.12% | Trim |
| 23 | ABT | Abbott Laboratories | -1.1% | EXIT | Sold out |
| 24 | RARE | Ultragenyx Pharmaceutical In | -1.2% | EXIT | Sold out |
| 25 | THC | Tenet Healthcare CORP | -1.2% | -59.88% | Trim |
| 26 | ACAD | Acadia Pharmaceuticals Inc | -1.4% | EXIT | Sold out |
| 27 | GMED | Globus Medical Inc - A | -1.4% | -55.04% | Trim |
| 28 | GEHC | GE Healthcare Technology | -1.5% | -50.26% | Trim |
| 29 | INCY | Incyte CORP | -1.8% | -33.56% | Trim |
| 30 | QGEN | Qiagen N.V. | -2% | EXIT | Sold out |
| 31 | GILD | Gilead Sciences Inc | -2% | -30.53% | Trim |
| 32 | BIIB | Biogen Inc | -2.8% | -41.61% | Trim |
| 33 | ✓ | Laboratory Corp. of America | -2.8% | EXIT | Sold out |
| 34 | CNC | Centene CORP | -3.4% | -89.73% | Trim |
According to official SEC Form 13F filings, Sector Gamma As reported a total U.S. public equity portfolio value of $461.0M across 28 disclosed positions in Q1 2024.
During Q1 2024, Sector Gamma As's top holdings by market value included MDT (10.1%)、PFE (9.7%)、BMY (7.6%). The largest single position, MDT, represented 10.1% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MDT, PFE, BMY) accounted for 30.9% of total reported equity market value during Q1 2024.
Top New Position Initiated
UHS
市值: $12.8M
Top Position Liquidated / Trimmed
Laboratory Corp. of America
前期市值: $11.5M
In Q1 2024, Sector Gamma As made 34 total portfolio adjustments, initiating 4 new buys, adding to 9 positions, trimming 15 holdings, and fully liquidating 6 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.